“The submission of the PMA supplement to the FDA for our second-generation LungFit PH device, which we announced yesterday, could be transformative for our business,” continued Lisi. “If approved, we believe this new system will unlock significant market potential. Coupled with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond Air (XAIR) and our shareholders.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air reports Q4 EPS (9c) vs. (37c) last year
- Options Volatility and Implied Earnings Moves Today, June 17, 2025
- Beyond Air submits FDA PMA supplement for LungFit PH
- Options Volatility and Implied Earnings Moves This Week, June 16 – June 20, 2025
- XAIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?